RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: MD-R-2024-11-27-150452 |   Pharmaceuticals

Historical data: 2018 - 2023

Forecast period: 2024 - 2031

Quantitative units: Revenue in USD million and CAGR from 2024 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Relapsed Acute Myeloid Leukemia Drug Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET

7.1 GLOBAL RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE (2018-2031) (USD MILLION)

8.1 GLOBAL RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

8.2 GLOBAL RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

9.1 GLOBAL RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

9.2 GLOBAL RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

10.1 GLOBAL RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)

10.2 GLOBAL RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)

11.1 NORTH AMERICA RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

11.2 NORTH AMERICA RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

11.3 NORTH AMERICA RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

11.4 NORTH AMERICA RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

11.5 NORTH AMERICA RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

11.6 NORTH AMERICA RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

12.1 EUROPE RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

12.2 EUROPE RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

12.3 EUROPE RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

12.4 EUROPE RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

12.5 EUROPE RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

12.6 EUROPE RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

13.1 ASIA PACIFIC RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

13.2 ASIA PACIFIC RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

13.3 ASIA PACIFIC RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

13.4 ASIA PACIFIC RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

13.5 ASIA PACIFIC RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

13.6 ASIA PACIFIC RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

14.1 LATIN AMERICA RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>

14.2 LATIN AMERICA RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

14.3 LATIN AMERICA RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

14.4 LATIN AMERICA RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

14.5 LATIN AMERICA RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

14.6 LATIN AMERICA RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>

16.1 4SC AG

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 AbbVie Inc

16.3 Actinium Pharmaceuticals Inc

16.4 Agios Pharmaceuticals Inc

16.5 Amgen Inc

16.6 Arog Pharmaceuticals Inc

16.7 Array BioPharma Inc

16.8 Astellas Pharma Inc

16.9 Astex Pharmaceuticals Inc

16.10 AstraZeneca Plc

16.11 AVEO Pharmaceutical

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

Market by Type :

aNK Program
AT-9283
BI-836858
binimetinib
BL-8040
Others

Market by Application :

Clinic
Hospital
Others

Companies

4SC AG
AbbVie Inc
Actinium Pharmaceuticals Inc
Agios Pharmaceuticals Inc
Amgen Inc
Arog Pharmaceuticals Inc
Array BioPharma Inc
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
AVEO Pharmaceutical

Single User License  : 3900$
Corporate License    : 7800$
Enquiry Before Buying
Request For Customization
Speak To Analyst

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE

    • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY

    • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH

    • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING

    • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.